FDA advises healthcare professionals of a new warning for Strattera, used to treat attention deficit disorder and hyperactivity in adults and children. The labeling of the drug is a warning in bold on the possibility of severe liver injury in patients who updates the Strattera. The labeling warns that severe liver damage can lead to liver failure in a small percentage of the progress of patients. He warned the doctors of the drug in patients who develop jaundice or laboratoryEvidence of liver damage. He also notes that the actual number of cases of serious liver damage from drugs is unknown because of underreporting. Manufacturer Strattera, Eli Lilly has agreed to send a letter to physicians alerting them to new information. The company will also update the patient package insert to include information about the signs and symptoms of liver problems. If you get unexpected side effects with Strattera, including liver damage, reported,directly to Eli Lilly and FDA MedWatch program. The addresses are available on our website. Additional Information: FDA MedWatch Safety Alert - Strattera (atomoxetine). www.fda.gov
Keywords: Strattera, Liver, Injury, FDA, Eli, Lilly, Patient, Safety, ADHD
ไม่มีความคิดเห็น:
แสดงความคิดเห็น